Immunotherapy combo tested for tough thyroid cancers
Disease control
Terminated
This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 79 patients with advanced thyroid cancer that had progressed despite treatment. The goal was to see if the combination could slow or stop cancer growth. The study was terminated early, so the full…
Phase: PHASE2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC